INDEX

A
Acarbose, diabetes prevention, 297
ACE inhibitors, *see* Angiotensin-converting enzyme inhibitors
ACP Medicine, resource features, 62
Adrenal incidentaloma,
  decision analysis case example,
  cost-effectiveness analysis, 221, 222
  quantitative analysis and decision model, 215, 219
  study results, 219, 221
  diagnosis and treatment, 214
Agency for Health Research and Quality (AHRQ), 121, 130
AHRQ, *see* Agency for Health Research and Quality
Alendronate, osteoporosis management, 354, 355
Angiotensin-converting enzyme (ACE) inhibitors, diabetes management, 5, 295, 309
Aspirin, diabetes management, 310
Atrial fibrillation, management decisions, 27

B–C
Bandolier, resource features, 64
Birthweight, diabetes risks, 293, 294
Bisphosphonates, osteoporosis management, 354, 355
BMT, *see* Bone marrow transplantation
Bone marrow transplantation (BMT),
  advocacy effects on health policy in chemotherapy, 132, 133
Calcitonin, osteoporosis management, 355, 357
CAM, *see* Complementary and alternative medicine
CATs, *see* Critically Appraised Topics
CDC, *see* Centers for Disease Control
CEA, *see* Cost-effectiveness analysis
Centers for Disease Control (CDC),
  National Diabetes Prevention and Control Program, 251, 252
CFS, *see* Chronic fatigue syndrome
Chromium, supplementation studies in diabetes, 338, 339
Chronic fatigue syndrome (CFS),
  depression comorbidity, 373
  epidemiology, 367
  neuroendocrine system role,
    abnormalities as cause or effect, 373, 374
    dehydroepiandrosteronedione, 372
    hypothalamic-pituitary-adrenal axis, 371, 372
    neurotransmitters, 372, 373
    overview, 370, 371
  prevention, 375
  stress role, 368, 369
  treatment, 374–376
Clinical Evidence, resource features, 62
Clinical investigation,
  clinical research centers, 156
  investigator types, 156, 157
  prospects, 162, 163
  strengths and weaknesses, 157–160
CMED, *see* Cochrane Metabolic and Endocrine Disorders Review Group
Cochrane, Archie, evidence-based medicine contributions, 12–14, 18, 20, 21
Cochrane Collaboration,
  Cochrane Library, 165, 166, 168, 169
  function, 167–169
  origins, 167
  systematic approach, 166, 167
Cochrane Database of Systematic Reviews,
  Inventory of Patient Decision Aids, 107
  resource features, 64, 65, 168, 169
  review publishing, *see* Cochrane Metabolic and Endocrine Disorders Review Group
  utilization, 176, 177
Cochrane Metabolic and Endocrine Disorders Review Group (CMED),
Australian Diabetes Satellite, 173
consumer participation, 174, 175
Editorial Base, 170
ditorial process, 170
origins, 169, 170
outcomes, 174
review publishing,
elements,
data extraction, 176
heterogeneity, 176
literature sifting, 175
study quality, 176
protocols, 171, 173
refereeing, 172
submission, 171
updates, 172
scope, 173
Complementary and alternative medicine (CAM),
diabetic patient use,
chromium supplementation, 338, 339
evidence-based medicine case example,
case resolution, 339, 340
literature review, 325–339
presentation, 324, 325
questions, 325
fish oil supplementation, 338, 339
herb studies,
American ginseng evidence-based appraisal, 327, 334
combination herbs,
334–337, 339
single herb trials, 326–334
prevalence, 323, 324
drug interactions, 323
market for herbs, 323
Cost-effectiveness analysis (CEA),
data requirements, 235
decision analysis, 214, 216–219, 221, 222
economic efficiency, 226, 227
economic solutions, 235, 236
health consequence valuation,
healthy years equivalent, 229, 231
quality adjusted life years, 229–231
incremental cost-effectiveness ratio, 232–234
limitations, 236, 237
overview, 225, 226
principles, 227, 228
Critically Appraised Topics (CATs),
resource features, 64
D
Decision analysis,
adrenal incidentaloma case example,
cost-effectiveness analysis, 221, 222
diagnosis and treatment, 214
quantitative analysis and decision model, 215, 219
study results, 219, 221
overview, 207, 208
principles,
cost-effectiveness analysis, 214, 216–219
decision tree, 208, 209
folding back of decision tree, 213
future event discounting, 213, 214
Markov model, 209, 210
outcome measure selection, 210–212
probability determination for chance events, 212
sensitivity analysis, 214
Decision making,
classes of decisions, 102
clinician role in patient decision making support,
close call decisions, 104
patient decision aids, 104–107
recommended options, 102–104
decision aids,
Cochrane Collaboration Systematic Review Inventory of Patient Decision Aids, 107
effects on decision quality, 105–107
evidence-based osteoporosis decision aid, 107, 110–115
integration into clinical practice, 108, 109
overview, 104, 105
patient response monitoring, 109
Decisional Conflict Scale, 108
evidence-based medicine principles,
evidence is not enough to make clinical decision, 26, 27
hierarchy of evidence in clinical decisions, 27–29
health policy decisions, see Health policy preferences, 27
values, 27
Diabetes mellitus,
complementary and alternative medicine, see Complementary and alternative medicine epidemiology, 241, 242
foot ulcer,
epidemiology, 316
evidence-based medicine resource utilization, 66
prognostic indicators, 316
treatment, 316, 317
health-related quality of life assessment,
clinical trials, 189, 194
epidemiological studies, 189
instruments, 187, 188, 190–193, 195, 199, 200
standard users guide, 195–197
observational studies, 144, 145, 147, 148
research translation to clinical practice, barriers, 243, 244
breakthrough series, 252, 253
Centers for Disease Control
National Diabetes Prevention and Control Program, 251, 252
challenges, 253, 254
focal points,
definition, 244
implementation, 245
institutionalization, 245, 246
populations reached, 244, 245
Health Disparities Program, 253
National Committee on Quality Assurance/American Diabetes Association Provider Recognition Program, 252
overview, 242, 243
practical clinical trial models, 249–251
RE-AIM framework, 246–249
Veterans Administration efforts, 252
Diabetes mellitus type 1
blood glucose target, 262
case studies of hypoglycemia management,
pancreas transplant alone while on pump, 270, 271
patient on insulin pump interested in islet transplantation, 268–270
patient on multiple daily insulin injections with hypoglycemia interested in insulin pump, 264, 265
patient on multiple daily insulin injections with hypoglycemia refusing other therapeutic options, 260, 261
patient on multiple daily insulin injections with success interested in insulin pump, 265, 267, 268
insulin preparations, 262, 264
patient education, 261
self-management trials, 259
Diabetes mellitus type 2
evidence-based medicine case study, application of evidence, 310, 311
early interventions, 304–311
evidence acquisition and appraisal, 304–307, 312–315
foot ulcer management, 315–317
insulin initiation, 311–315
prevention and management,
bariatric surgery, 297, 298
lifestyle modification, 296, 307, 308
pharmacotherapy, 297, 308–310
recommendations, 298, 299
trials, 291
prognosis, 304
risk factors,
age, 289, 290
birthweight and early life
influences, 293, 294
diet, 294, 295
ethnicity, 290, 292
family history, 292
gestational diabetes, 293
hypertension, 295, 309
impaired fasting glucose, 292, 293
impaired glucose tolerance,
292, 293
obesity and central fat
distribution, 290
polycystic ovary syndrome, 295
schizophrenia, 295, 296
sedentary lifestyle, 295
smoking, 295, 308
screening for complications, 307
trends, 289, 303

Diagnostic thinking,
analytic thinking, 72, 73
clinical care research evidence, 73
evidence integration, 79–82
illustrative cases, 69, 70
modes, 70–72
research types in diagnostic decisions,
76–78
traditions,
anatomic, 74
belief-based, 74
biopsychosocial, 75
criteria-based, 74
descriptive, 74
pathophysiological, 75
probabilistic, 75

Diet, diabetes risks, 294, 295

E
EBM, see Evidence-based medicine
Economic efficiency, see Cost-effectiveness analysis
Education, see Training, evidence-based endocrinology
EQ-5D, health-related quality of life assessment, 186, 187
Evidence-based medicine (EBM),
contributions to endocrinology,
literature knowledge, 1, 2
normal definition setting, 3–5
research agenda setting, 2, 3
training, 6, 7
treatment objective setting, 5
definition, 166
hierarchy of preprocessed evidence, 31, 32
historical perspective, 11–22
humanism and social responsibility, 30–31
principles,
evidence is not enough to make
clinical decision, 26, 27
hierarchy of evidence in clinical
decisions, 27–29
resources, see Resources, evidence in endocrinology
training, see Training, evidence-based endocrinology

F–H
Feinstein, Alvan, evidence-based medicine contributions, 14–16, 18, 22
Fish oil, supplementation studies in diabetes, 338, 339
Foot ulcer, see Diabetes mellitus
Glucocorticoid-induced osteoporosis, management, 359, 360
Guyatt, Gordon, evidence-based medicine contributions, 18, 19
HCV, see Hepatitis C virus
Health Disparities Program, 253
Health policy,
evidence-based decisions,
barriers, 119, 120
conflict resolution,
assigning values to health outcomes versus intermediate outcomes, 123, 124
cost considerations, 126, 127 examples, 127–130
perspective of decision makers and stakeholders, 124, 125
synthesis of evidence, 121–123
framework, 120, 121
evidence-based medicine,
implementation solutions, 134–136
intersection, 117–120
medical liability, 134
political lobbying and advocacy, 130–134
Health-related quality of life (HRQL),
definition, 180, 181
diabetes mellitus assessment,
clinical trials, 189, 194
epidemiological studies, 189
instruments, 187, 188, 190–193, 195, 199, 200
standard users guide, 195–197
importance, 179, 180
instruments,
EQ-5D, 186, 187
generic instruments, 181, 186, 187
interpretation, 185
preference instruments, 182, 183, 188
reliability, 185
responsiveness, 185
SF-36, 186
specific instruments, 181, 182, 187, 189, 195, 201
validity, 183–185
WHOQOL-100, 187
resources for endocrinology,
databases, 198
journals, 198
Healthy years equivalent (HYE), health consequence valuation in cost-effectiveness analysis, 229, 231
Hepatitis C virus (HCV),
screening recommendations, 127, 128
viral load and disease progression, 123, 124
Herbs, see Complementary and alternative medicine
Hierarchy of evidence, clinical decision making, 27–29
HIV, see Human immunodeficiency virus
Hormone replacement therapy,
osteoporosis management, 353
HRQL, see Health-related quality of life,
Human immunodeficiency virus (HIV),
 viral load and AIDS progression, 123, 124
HYE, see Healthy years equivalent
Hyperparathyroidism, observational studies, 143
Hypertension, diabetes risks, 295, 309
Hypothyroidism, screening recommendations, 128–130
I–L
Ibandronate, osteoporosis management, 355
ICD, see Implantable cardiac defibrillator
Implantable cardiac defibrillator (ICD),
cost considerations, 125
Insulin,
diabetes type 2 management, 313, 314
preparations, 262, 264
Journals,
evidence-based medicine in keeping up to date, 1, 2
health-related quality of life resources, 198
Kyphoplasty, osteoporosis management, 358
Liability, effects on health policy, 134
M–N
Markov model, decision analysis, 209, 210
Mayo Track, patient education, 92, 93
Medical liability, see Liability
Medline, resource features, 65
MedlinePlus, resource features, 63
Metformin, diabetes prevention and management, 297, 308, 309, 312
National Electronic Library of Health, resource features, 63
NLM Gateway, resource features, 63
Obesity, clinical assessment, overview, 276
severe medically complicated case presentation, 276, 277
diabetes risks, 290
epidemiology, 275
weight loss, approaches, 277, 278
efficacy outcomes, 275, 284, 285
goals, 276
literature analysis, 277–284
Observational studies, analytic studies, case–control studies, 146, 147
cohort studies, 145, 146, 148
descriptive studies, 142–145
overview, 142
prospects, 151, 152
randomized control trial complementation, stage setting, 148, 149
treatment effectiveness evaluation, 150, 151
Orlistat, diabetes prevention, 297
Osteoporosis,
bone mineral density measurements, central skeleton, 346, 347
peripheral skeleton, 345, 346
bone turnover markers, 350
case example of evidence-based medicine resource utilization, 65, 66
economic impact, 343
evidence-based osteoporosis decision aid, 107, 110–115
fracture incidence, 344
laboratory testing, 348–350
management,
calcitonin, 355, 356
combination therapy, 357, 358
glucocorticoid-induced osteoporosis, 359, 360
hormone therapy, 353
lifestyle interventions, 351
men, 358, 359
nutrition, 350, 351
parathyroid hormone, 356, 357
pharmacotherapy, 351–355
surgery, 358
observational studies, 149–151
risk factors, 348
screening recommendations, 344, 345
trends, 149
Ottawa Personal Decision Guide, 108
Ovid’s Evidence-Based Medicine Reviews Service, resource features, 64, 66
Parathyroid hormone (PTH), osteoporosis management, 356, 357
Patient education,
decision making aids, see Decision making
diabetes mellitus type 1 self-management, 261
health information and access to medical evidence, 91, 92
information system implementation, barriers, 93, 94
patient solutions, 95
provider solutions, 94
learning environment, 88, 89
Mayo Track, 92, 93
pharmaceutical industry advertising impact, 89
telecare, 93
Patient-Oriented Evidence that Matters (POEMs), resource features, 63, 64
Physician information,
 improvement of utility, evidence-based medicine at point of care, 89, 90
information technology, 90
information system implementation, barriers, 93, 94
patient solutions, 95
provider solutions, 94
learning strategies, 88
Pioglitazone, diabetes management, 309, 312
POEMs, see Patient-Oriented Evidence that Matters
Polycystic ovary syndrome, diabetes risks, 295
Preferences, decision making role, 27
Provider Recognition Program, 252
PTH, see Parathyroid hormone
PubMed, resource features, 65

Q–R

QALYs, see Quality adjusted life years
Quality adjusted life years (QALYs), health consequence valuation in cost-effectiveness analysis, 229–231
Quality of life, see Health-related quality of life
Raloxifene, osteoporosis management, 353, 354, 357
Randomized control trial (RCT), classification,
Cochrane reviews, 122
US Preventive Services Task Force, 121–123
importance, 141
N-of-1 study design, 28, 155
observational study complementation,
stage setting, 148, 149
treatment effectiveness evaluation, 150, 151
strengths and weaknesses, 160–162
RCT, see Randomized control trial
RE-AIM framework, research translation to clinical practice, 246–249
Resources, evidence in endocrinology, hierarchy, 61, 62, 67
problem-based exercises, 65–67
studies, 65
synopses, 63, 64
syntheses, 64, 65
systems, 62, 63
Risedronate, osteoporosis management, 354, 355
Rosiglitazone, diabetes management, 309, 312

S–T

Sackett, David, evidence-based medicine contributions, 16–18
Schizophrenia, diabetes risks, 295, 296
Sedentary lifestyle, diabetes risks, 295
SF-36, health-related quality of life assessment, 186
Smoking, diabetes risks, 295, 308
Statins, diabetes management, 309, 310
initiation criteria, 4
Tamoxifen, osteoporosis management, 353
Thyroid module, management, 25, 26
Traditional Chinese medicine, diabetes studies, 334, 336, 337, 339
Training, evidence-based endocrinology, Accreditation Council for Graduate Medical Examination requirements, 36, 37
barriers, 45, 46
competency evaluation, computer and technology skills, 45
global ratings, 45
knowledge and skills, 42, 43
performance, 43, 44
readiness or attitudes, 44, 45
fellowship curricula, 36
graduate medical education, freestanding curricula, 38–40
hidden curriculum, 41
integrated curricula, 39, 41
journal clubs, 38
subspecialty fellowship training programs, 36–38
learning theory, 88
overview, 6, 7, 35, 36
recommendations, acquiring evidence, 50
applying evidence, 50, 51
asking fruitful clinical questions, 49
decision-making framework for harm question, 51, 52
evaluation, 51, 53
freestanding curricula, 46, 47
hidden curriculum, 51
integrated curricula, 47, 48
learning infrastructure, 46
resources, 53, 54
TRIP, see Turning Research into Practice
Troglitazone, diabetes management, 312
Turning Research into Practice (TRIP), resource features, 63

U
UpToDate, resource features, 62
US Preventive Services Task Force (USPSTF),
Agency for Health Research and Quality, 121, 130
breast cancer screening recommendations, 122

V–Z
hepatitis C virus screening recommendations, 127, 128
hypothyroidism screening recommendations, 128–130
randomized control trial, 121–123
USPSTF, see US Preventive Services Task Force
Values, decision making role, 27
Vertebroplasty, osteoporosis management, 358
WHOQOL-100, health-related quality of life assessment, 187
Zollinger-Ellison Syndrome, case example of evidence-based medicine resource utilization, 66, 67